MedPath

A study to assess different investigational drugs for the treatment of hidradenitis suppurativa

Phase 1
Active, not recruiting
Conditions
Hidradenitis suppurativa
MedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858
Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Registration Number
EUCTR2018-002757-30-FR
Lead Sponsor
ovartis Pharma AG
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Recruiting
Sex
All
Target Recruitment
90
Inclusion Criteria

- Male or female, age 18-65 years, at least 50 kg body weight with moderate to severe HS
- Clinically diagnosed HS for at least 12 months prior to screening
- For Cohort A (iscalimab): at least 5 inflammatory lesions, no more than 10 fistulae and at least two anatomical area involved with HS lesions
- For Cohort B (LYS006): at least 3 inflammatory lesions; no more than 10 fistulae and at least two anatomical areas involved with HS lesions

Other protocol-defined inclusion criteria may apply
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 89
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 1

Exclusion Criteria

- Use of other investigational drugs at the time of screening, or within 30 days or 5 half-lives of randomization, whichever is longer; or
longer if required by local regulations
- Women of childbearing potential, unless they are using highly effective methods of contraception during dosing and for a minimum of 12 weeks after stopping medication for cohort A (iscalimab) and a minimum of 2 weeks after the last study drug administration for cohort B (LYS006).
- Pregnant or nursing (lactating) women

Other protocol-defined exclusion criteria may apply

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath